A study of people who inject drugs found a significant increase in the risk of infective endocarditis, a serious infection of the lining of the heart, possibly linked to increasing use of the opioid hydromorphone. The study is published in CMAJ (Canadian Medical Association Journal).
Infective endocarditis can be life-threatening.
"We observed a substantial increase in the risk of infective endocarditis among people who inject drugs, which is associated with hydromorphone's increasing share of the prescription opioid market," write the authors, including first author Dr. Matthew Weir, associate scientist at Lawson Health Research Institute and assistant professor at Schulich School of Medicine & Dentistry, Western University, London, Ontario.
Researchers looked at Ontario data on drug users from linked health administrative databases at ICES between April 2006 and September 2015. There were 60 529 admissions to hospital of people who inject drugs and, of these, 733 had infective endocarditis linked to injecting drugs. Although admission rates for people who inject drugs were stable over the study period, the risk of infective endocarditis increased from 13.4 admissions every three months (fourth quarter 2011) to 35.1 admissions every three months in the period afterwards.
Whereas the percentage of opioid prescriptions attributed to controlled-release oxycodone declined rapidly when it was removed from the market by its manufacturer in the fourth quarter of 2011, hydromorphone prescriptions increased from 16 percent at the start of the study to 53 percent by the end.
The researchers expected that an increase in risk of infective endocarditis would occur when controlled-release oxycodone was removed from the Canadian market; however, they found that the rise began before removal.
"Although our observations do not support our hypothesis that the loss of controlled-release oxycodone increased the use of hydromorphone, they do support our suspicion that hydromorphone may be playing a role in the increasing risk of infective endocarditis," says coauthor Dr. Michael Silverman, associate scientist at Lawson and associate professor at Schulich School of Medicine & Dentistry.
The increase in the risk of infective endocarditis is consistent with the findings of other studies, but the observed timing of the increase was novel.
"Both the rise in this severe complication of injection drug use and the possible association with hydromorphone require further study," suggest the authors.
"The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis" was published Jan. 28, 2019.
Source: Canadian Medical Association Journal